Recommendation for validation and quality assurance of non‐invasive prenatal testing for foetal blood groups and implications for <scp>IVD</scp> risk classification according to <scp>EU</scp> regulations

Frederik Banch Clausen(University of Copenhagen), Tobias J. Legler(Universitätsmedizin Göttingen), Gregor Bein(Justus-Liebig-Universität Gießen), D. W. M. Schwartz(Medical University of Vienna), Åsa Hellberg, Christoph Gassner(DRK-Blutspendedienst Baden-Württemberg - Hessen), Katarzyna Guz(Instytut Hematologii i Transfuzjologi), Christine Henny(Swiss Red Cross), Katri Haimila(Finnish Red Cross), Agnieszka Orzińska(Instytut Hematologii i Transfuzjologi), Masja de Haas(Dutch Blood Transfusion Society), William J. Lane(Brigham and Women's Hospital), C. Ellen van der Schoot(Sanquin), Martin L. Olsson(Lund University), Catherine A. Hyland(Australian Red Cross Lifeblood), Thierry Peyrard(Inserm), Yanli Ji(Guangzhou Blood Center), Núria Nogués(Banc de Sang i Teixits), Tadeja Dovč Drnovšek(Blood Transfusion Centre of Slovenia), Agneta Wikman(Karolinska University Hospital), Christof Weinstock(Universität Ulm), Steinunn Thorlacius(deCODE Genetics (Iceland)), Peter Bugert(Heidelberg University), Kirsten Sørensen(Oslo University Hospital), Helen O’Brien(Australian Red Cross Lifeblood), Willy A. Flegel(National Institutes of Health Clinical Center), Kirstin Finning(National Health Service), Gregory A. Denomme(Grifols (United States))
Vox Sanguinis
June 21, 2021
Cited by 21


Related Papers